Abstract
Leishmaniasis is a diverse group of neglected diseases caused by protozoan parasite of genus Leishmania and transmitted by the bite of a female phlebotomine sand fly. These diseases stand as a major health problem worldwide, especially in their visceral form. Despite innumerable studies on leishmaniasis, many questions are still unanswered. One of the main challenges is the presence of different Leishmania species and various clinical manifestations, complicating the therapeutic approach. There are many available antileishmanial agents, but the drug of choice is still out of reach, since almost all available drugs share several limitations and many of them are expensive with severe side effects or have a markedly reduced effectiveness. Immunosuppressed patients should also be given a special attention which represents an additional challenge. In the meantime, the combination of local and parenteral therapies with existing drugs remain a priority to improve the efficacy and to shorten the duration of the treatment. This review was undertaken to highlight the chemotherapeutic strategies, their mechanisms of action and main limitations.
Keywords: Leishmaniasis, treatment, chemotherapy, combination therapy, immunomodulation.
Current Pharmaceutical Design
Title:Treatment of Leishmaniasis: A Review and Assessment of Recent Research
Volume: 21 Issue: 17
Author(s): Ehab Kotb Elmahallawy and Ahmad Agil
Affiliation:
Keywords: Leishmaniasis, treatment, chemotherapy, combination therapy, immunomodulation.
Abstract: Leishmaniasis is a diverse group of neglected diseases caused by protozoan parasite of genus Leishmania and transmitted by the bite of a female phlebotomine sand fly. These diseases stand as a major health problem worldwide, especially in their visceral form. Despite innumerable studies on leishmaniasis, many questions are still unanswered. One of the main challenges is the presence of different Leishmania species and various clinical manifestations, complicating the therapeutic approach. There are many available antileishmanial agents, but the drug of choice is still out of reach, since almost all available drugs share several limitations and many of them are expensive with severe side effects or have a markedly reduced effectiveness. Immunosuppressed patients should also be given a special attention which represents an additional challenge. In the meantime, the combination of local and parenteral therapies with existing drugs remain a priority to improve the efficacy and to shorten the duration of the treatment. This review was undertaken to highlight the chemotherapeutic strategies, their mechanisms of action and main limitations.
Export Options
About this article
Cite this article as:
Elmahallawy Ehab Kotb and Agil Ahmad, Treatment of Leishmaniasis: A Review and Assessment of Recent Research, Current Pharmaceutical Design 2015; 21 (17) . https://dx.doi.org/10.2174/1381612821666141231163053
DOI https://dx.doi.org/10.2174/1381612821666141231163053 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanomedicine based on Nucleic Acids: Pharmacokinetic and Pharmacodynamic Perspectives
Current Pharmaceutical Biotechnology Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids
Current Drug Metabolism Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design Cancer Diagnosis Through IsomiR Expression with Machine Learning Method
Current Bioinformatics A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets Unmet Needs in Ovarian Cancer: Dividing Histologic Subtypes to Exploit Novel Targets and Pathways
Current Cancer Drug Targets Clinical, Molecular- and Cytogenetic Analysis of a Case of Severe Radio- Sensitivity
Current Genomics Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Multi-Target QSAR and Docking Study of Steroids Binding to Corticosteroid-Binding Globulin and Sex Hormone-Binding Globulin
Current Computer-Aided Drug Design RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design Possible Role of PTEN Expression in Discriminating Benign Endometrial Hyperplasia from Atypical Hyperplasia/Endometrial Intraepithelial Neoplasia in a Series of Egyptian Patients
Current Women`s Health Reviews Bone Modulating Bioactive Natural Compounds: Review
Current Bioactive Compounds Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry Emerging Role of Mucins in Epithelial to Mesenchymal Transition
Current Cancer Drug Targets PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
Current Pharmaceutical Design The Role of Apoptotic Dysfunction in the Pathogenesis of Endometriosis
Current Women`s Health Reviews Drug Repurposing in Anticancer Reagent Development
Combinatorial Chemistry & High Throughput Screening Salinomycin Modulates the Expression of mRNAs and miRNAs Related to Stemness in Endometrial Cancer
Current Pharmaceutical Biotechnology